NDAORALTABLET
Approved
Oct 1963
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RENESE-R is a fixed-dose oral antihypertensive combination tablet containing polythiazide (a thiazide diuretic) and reserpine (an antiadrenergic agent). It was developed to treat hypertension by combining diuretic and sympatholytic mechanisms. This product represents a legacy approach to blood pressure management from the 1960s era.
LOE Approaching
Declining product with minimal modern commercial infrastructure; roles are primarily maintenance-focused with limited growth opportunity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate this is a legacy product with minimal active headcount and career opportunity. Working on RENESE-R offers limited visibility, skill-building, or mobility within modern pharmaceutical organizations.
Brand ManagerSales Representative
Worked on RENESE-R at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.